POC NRL Allergy Skin Test Need Highlighted At FDA Latex Videoconference
This article was originally published in The Gray Sheet
The need for a commercially available point-of-care rapid diagnostic test for natural rubber latex allergy was emphasized at a May 5 videoconference on natural rubber latex (NRL) allergy.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.